InvestSMART

Argenica Therapeutics Limited (ASX: AGN) - Announcements

Current share price for AGN : $0.180 0.015 (7.69%)+

ASX company news and announcements for Argenica Therapeutics Limited (AGN) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Argenica Therapeutics Limited (AGN) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Argenica Therapeutics Limited (AGN), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Argenica Therapeutics Limited (AGN)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$23 Appendix 4G & Corporate Governance Statement 26 Aug 2026 4:35PM $0.190 $0.180 fallen by 5.26%
$23 Appendix 4E & Annual Report to 30 June 2026 26 Aug 2026 4:29PM $0.190 $0.180 fallen by 5.26%
$23 Notification of cessation of securities - AGN 13 Aug 2026 5:32PM $0.170 $0.180 risen by 5.88%
$23 Investor Presentation - Techknow Conference 27 Jul 2026 9:13AM $0.155 $0.180 risen by 16.13%
$23 Quarterly Activities/Appendix 4C Cash Flow Report 24 Jul 2026 9:18AM $0.150 $0.180 risen by 20%
$23 ARG007 Shows Significant Neuroprotection in Concussion Study 16 Jul 2026 8:27AM $0.140 $0.180 risen by 28.57%
$23 Investor Webinar 11 Jun 2026 8:33AM $0.110 $0.180 risen by 63.64%
$23 Investor Presentation 11 Jun 2026 8:33AM $0.110 $0.180 risen by 63.64%
$23 ARG007 (Xaranetide) Completes All Three FDA Requested Assays 11 Jun 2026 8:33AM $0.110 $0.180 risen by 63.64%
$23 WHO Confirms Xaranetide as INN for ARG-007 10 Jun 2026 8:19AM $0.115 $0.180 risen by 56.52%
$23 Notification of cessation of securities - AGN 9 Jun 2026 2:13PM $0.115 $0.180 risen by 56.52%
$23 Release of Securities from Voluntary Escrow 26 May 2026 9:52AM $0.115 $0.180 risen by 56.52%
$23 IND Application Advanced With Successful Completion of Assay 21 May 2026 9:01AM $0.135 $0.180 risen by 33.33%
$23 Clinical Advisory Committee Established to Advance Phase 2b 14 May 2026 9:15AM $0.150 $0.180 risen by 20%
$23 Quarterly Activities/Appendix 4C Cash Flow Report 29 Apr 2026 8:20AM $0.180 $0.180 fallen by 0%
$23 Investor Presentation - Ignite Conference 16 Apr 2026 9:15AM $0.160 $0.180 risen by 12.50%
$23 Presentations at European Stroke Organisation Conference 26 Mar 2026 8:13AM $0.165 $0.180 risen by 9.09%
$23 Argenica Receives $3.97m R&D Tax Incentive Cash Rebate 17 Mar 2026 8:19AM $0.200 $0.180 fallen by 10%
$23 Half Yearly Report and Accounts 11 Feb 2026 8:17AM $0.285 $0.180 fallen by 36.84%
$23 Investor Presentation - Euroz Hartleys Healthcare Conference 5 Feb 2026 8:23AM $0.290 $0.180 fallen by 37.93%
$23 Successful Applicaton for EMA Paediatric Waiver 2 Feb 2026 9:01AM $0.280 $0.180 fallen by 35.71%
$23 Quarterly Activities/Appendix 4C Cash Flow Report 28 Jan 2026 8:15AM $0.255 $0.180 fallen by 29.41%
$23 Final Director's Interest Notice 2 Jan 2026 4:53PM $0.305 $0.180 fallen by 40.98%
$23 Non-Executive Chair Resignation 29 Dec 2025 8:27AM $0.270 $0.180 fallen by 33.33%
$23 AI Analysis Reveals Efficacy In Severe Stroke Patients 11 Dec 2025 9:11AM $0.270 $0.180 fallen by 33.33%

1 - 25 of 294 results

Page 1 of 12

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.